

Supplemental Table 1. Sequence type and phenotype of parental strains.

<b>Strain</b>	<b><i>hsdS</i> allele<sup>(1, 2)</sup></b>	<b>Transparent vs opaque</b>	<b>Sequence type<sup>(3)</sup></b>	<b>PubMLST id</b>
0556-97	B	Mixed	ST199	38163
3031-06	B	Mixed	ST199	38164

Supplemental Table 2. Primers used in this study

Primer (direction)	Location	Sequence	Purpose (fragment)	Source
5482 (F)	<i>rpsL</i> <sup>-</sup>	CTGGAAATTCAACCAAAAATAAAA AAACACAGGAG	Transformation into 0556-97 and 3031-06	(4)
3482 (R)	<i>rpsL</i> <sup>-</sup>	CTAGGGCCCTTCCTTATGCTT TTGGAC	Transformation into 0556-97 and 3031-06	(4)
5168 (F)	<i>wzx</i>	TTGGTCTGATTATGCACCTC	Creation of <i>wciZ</i> variant constructs (BLS143, 157, 171); Sequencing <i>wciZ</i> region of clinical isolates	This study
3162 (R)	<i>wciZ/JS</i>	CAAACTTCTAGACTGCATATTA CCTTCTCTCC	Creation of <i>wciZ</i> deletion construct (BLS143); Sequencing <i>wciZ</i> region of clinical isolates	This study
5169 (F)	<i>wciZ/JS</i>	GTAATATGCAGTCTAGAAGTTT GATTTTAATGG	Creation of <i>wciZ</i> deletion construct (BLS143)	This study
3163 (R)	JS/ <i>wchX</i>	GATTTAACCGCGCCCCTTCCTT ATGCTTTG	Creation of <i>wciZ</i> deletion construct (BLS143)	This study
5170 (F)	JS/ <i>wchX</i>	CATAAGGAAAGGGCGCGATT AATCACCTAAAGC	Creation of <i>wciZ</i> deletion construct (BLS143); Sequencing <i>wciZ</i> region of clinical isolates	This study
3164 (R)	<i>wchX</i>	CCCATCATCTCTGAAAGTAG	Creation of <i>wciZ</i> variant constructs (BLS143, 157, 171); Sequencing <i>wciZ</i> region of clinical isolates	This study
3229 (R)	<i>wciZ</i>	CTGCATATTACCTTCTCTCC	BLS171 <i>wciZ</i> construct, 5' fragment	This study
5256 (F)	<i>wciZ</i>	GGAGAGAAGGTAATATGCAG	BLS171 <i>wciZ</i> construct, 3' fragment	This study
5508 (F)	<i>dexB</i>	GCCGTAGTCTATCAAGTCTATC CAA	<i>cps</i> locus deletion construct (BLS147)	This study
3493 (R)	<i>aliA</i>	TGCTTCCAAGGATTGTTCATAG ATTG	<i>cps</i> locus deletion construct (BLS147)	This study

Supplemental Table 3. *cps* loci differences between a clinical isolate 0556-97 (serotype 15B) used in this study and a reference serotype 15B strain (7904/39 strain) in literature (5)

Nucleotide <sup>a</sup>	7904/39 <sup>b</sup>	BLS141 <sup>c</sup>	Gene	Function	Amino Acid <sup>d</sup> difference
293-1203	<i>aliB</i> , IS1630 tnp	IS1202 tnp			
1204-3382		>90 snps	<i>wzg-wzh</i>	regulatory region	
5743	A	C	<i>wchA</i>	initiating glycosyltransferase	Arg318Arg
5772	G	A	<i>wchA</i>	initiating glycosyltransferase	<b>Gln327Gln</b>
7296	G	A	<i>wzy</i>	polymerase	<b>Met64Ile</b>
7352	G	T	<i>wzy</i>	polymerase	<b>Leu83Phe</b>
10200	A	G	<i>wchM</i>	$\beta$ -galactosyltransferase	Val298Val
10841	T	C	<i>wchN</i>	$\alpha$ -galactosyltransferase	<b>Val188Ala</b>
12344	A	G	<i>wzx</i>	flippase	<b>Ile385Val</b>
12947	G	A	intergenic	N/A <sup>e</sup>	N/A
14387	C	A	<i>wchX</i>	glycerol phosphotransferase	<b>Gln130Lys</b>
16712	T	C	<i>gtp2</i>	CDP-2-glycerol synthesis	<b>Val162Ala</b>
17156	A	T	<i>gtp3</i>	CDP-2-glycerol synthesis	Val70Val
17393	C	T	<i>gtp3</i>	CDP-2-glycerol synthesis	Arg149Arg
17869-18375		9 snps	IS1381 and IS1671 tnp		

<sup>a</sup> Nucleotide number is with respect to the reference sequence (GenBank Accession No. CR931664.1)


<sup>b</sup> Accession no. CR931664.1

<sup>c</sup> Accession no. KY750633


<sup>d</sup> Amino acid sequence differences are with respect to 7904/39. Boldface indicates a missense substitution.

<sup>e</sup> N/A means not applicable.

### fs15b



### Pool H



Supplemental Figure 1. Parental clinical isolates (0556-97 and 3031-06) and the transformed reference strains (BLS141 and BLS142, respectively) have equivalent amounts of O-acetylation and capsule based on fs15b and Pool H binding, respectively. Error bars indicate standard deviation of the three intra-assay replicates.

## REFERENCES

1. **Manso AS, Chai MH, Atack JM, Furi L, De Ste Croix M, Haigh R, Trappetti C, Ogunniyi AD, Shewell LK, Boitano M, Clark TA, Korlach J, Blades M, Mirkes E, Gorban AN, Paton JC, Jennings MP, Oggioni MR.** 2014. A random six-phase switch regulates pneumococcal virulence via global epigenetic changes. *Nature Communications* **5**:5055.
2. **Li J, Li JW, Feng Z, Wang J, An H, Liu Y, Wang Y, Wang K, Zhang X, Miao Z, Liang W, Sebra R, Wang G, Wang WC, Zhang JR.** 2016. Epigenetic Switch Driven by DNA Inversions Dictates Phase Variation in *Streptococcus pneumoniae*. *PLoS Pathog* **12**:e1005762.
3. **Enright MC, Spratt BG.** 1998. A multilocus sequence typing scheme for *Streptococcus pneumoniae*: identification of clones associated with serious invasive disease. *Microbiology* **144** ( Pt 11):3049-3060.
4. **Calix JJ, Oliver MB, Sherwood LK, Beall BW, Hollingshead SK, Nahm MH.** 2011. *Streptococcus pneumoniae* serotype 9A isolates contain diverse mutations to *wcjE* that result in variable expression of serotype 9V-specific epitope. *Journal of Infectious Diseases* **204**:1585-1595.
5. **Bentley SD, Aanensen DM, Mavroidi A, Saunders D, Rabbinowitsch E, Collins M, Donohoe K, Harris D, Murphy L, Quail MA, Samuel G, Skovsted IC, Kaltoft MS, Barrell B, Reeves PR, Parkhill J, Spratt BG.** 2006. Genetic analysis of the capsular biosynthetic locus from all 90 pneumococcal serotypes. *PLoS Genet* **2**:e31.